These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 30010694)

  • 1. Cost-Effectiveness of Renal Denervation Therapy for Treatment-Resistant Hypertension: A Best Case Scenario.
    Chowdhury EK; Reid CM; Zomer E; Kelly DJ; Liew D
    Am J Hypertens; 2018 Sep; 31(10):1156-1163. PubMed ID: 30010694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential lifetime cost-effectiveness of catheter-based renal sympathetic denervation in patients with resistant hypertension.
    Dorenkamp M; Bonaventura K; Leber AW; Boldt J; Sohns C; Boldt LH; Haverkamp W; Frei U; Roser M
    Eur Heart J; 2013 Feb; 34(6):451-61. PubMed ID: 23091202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of renal denervation therapy for the treatment of resistant hypertension in the UK.
    Gladwell D; Henry T; Cook M; Akehurst R
    Appl Health Econ Health Policy; 2014 Dec; 12(6):611-22. PubMed ID: 25086585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of renal denervation therapy for the treatment of resistant hypertension in The Netherlands.
    Henry TL; De Brouwer BF; Van Keep MM; Blankestijn PJ; Bots ML; Koffijberg H
    J Med Econ; 2015 Jan; 18(1):76-87. PubMed ID: 25367314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension.
    Geisler BP; Egan BM; Cohen JT; Garner AM; Akehurst RL; Esler MD; Pietzsch JB
    J Am Coll Cardiol; 2012 Oct; 60(14):1271-7. PubMed ID: 22981547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central pulse pressure predicts BP reduction after renal denervation in patients with treatment-resistant hypertension.
    Ott C; Schmid A; Toennes SW; Ditting T; Veelken R; Uder M; Schmieder RE
    EuroIntervention; 2015 May; 11(1):110-6. PubMed ID: 25982653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of renal denervation on tissue Na
    Ott C; Kopp C; Dahlmann A; Schmid A; Linz P; Cavallaro A; Hammon M; Ditting T; Veelken R; Uder M; Titze J; Schmieder RE
    Clin Res Cardiol; 2018 Jan; 107(1):42-48. PubMed ID: 28845508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of self-management of blood pressure in hypertensive patients over 70 years with suboptimal control and established cardiovascular disease or additional cardiovascular risk diseases (TASMIN-SR).
    Penaloza-Ramos MC; Jowett S; Mant J; Schwartz C; Bray EP; Sayeed Haque M; Richard Hobbs FD; Little P; Bryan S; Williams B; McManus RJ
    Eur J Prev Cardiol; 2016 Jun; 23(9):902-12. PubMed ID: 26603745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Copeptin Levels in Patients With Treatment-Resistant Hypertension Before and 6 Months After Renal Denervation.
    Bosch A; Schmid A; Ott C; Kannenkeril D; Karg MV; Ditting T; Veelken R; Uder M; Schmieder RE
    Am J Hypertens; 2020 Feb; 33(2):182-189. PubMed ID: 31555795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telemonitoring and self-management in the control of hypertension (TASMINH2): a cost-effectiveness analysis.
    Kaambwa B; Bryan S; Jowett S; Mant J; Bray EP; Hobbs FD; Holder R; Jones MI; Little P; Williams B; McManus RJ
    Eur J Prev Cardiol; 2014 Dec; 21(12):1517-30. PubMed ID: 23990660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atrial Remodeling Following Catheter-Based Renal Denervation Occurs in a Blood Pressure- and Heart Rate-Independent Manner.
    Schirmer SH; Sayed MM; Reil JC; Lavall D; Ukena C; Linz D; Mahfoud F; Böhm M
    JACC Cardiovasc Interv; 2015 Jun; 8(7):972-80. PubMed ID: 26003031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-in-Man Experience with a Novel Catheter-Based Renal Denervation System of Ultrasonic Ablation in Patients with Resistant Hypertension.
    Chernin G; Szwarcfiter I; Scheinert D; Blessing E; Diehm N; Dens J; Walton A; Verheye S; Shetty S; Jonas M
    J Vasc Interv Radiol; 2018 Aug; 29(8):1158-1166. PubMed ID: 29921526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal denervation in moderate treatment-resistant hypertension.
    Ott C; Mahfoud F; Schmid A; Ditting T; Sobotka PA; Veelken R; Spies A; Ukena C; Laufs U; Uder M; Böhm M; Schmieder RE
    J Am Coll Cardiol; 2013 Nov; 62(20):1880-6. PubMed ID: 23850901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective.
    Ademi Z; Zomer E; Tonkin A; Liew D
    Int J Cardiol; 2018 Nov; 270():54-59. PubMed ID: 30220379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal Sympathetic Denervation: A Viable Option for Treating Resistant Hypertension.
    Schlaich MP
    Am J Hypertens; 2017 Sep; 30(9):847-856. PubMed ID: 28338871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistant Hypertension and Renal Nerve Denervation.
    Denker MG; Cohen DL
    Methodist Debakey Cardiovasc J; 2015; 11(4):240-4. PubMed ID: 27057294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective.
    Zomer E; Si S; Hird TR; Liew D; Owen AJ; Tonkin A; Reid CM; Ademi Z
    Eur J Prev Cardiol; 2019 May; 26(8):858-868. PubMed ID: 30526023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.